Search

Your search keyword '"Lam, Carolyn S"' showing total 1,550 results

Search Constraints

Start Over You searched for: Author "Lam, Carolyn S" Remove constraint Author: "Lam, Carolyn S"
1,550 results on '"Lam, Carolyn S"'

Search Results

1. Insights on prevalence and incidence of anemia and rapid up-titration of oral heart failure treatment from the STRONG-HF study

2. Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes

11. Clinical Correlates and Prognostic Impact of Cognitive Dysfunction in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF

12. Author Correction: Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes

18. Multimorbidity in patients with acute heart failure across world regions and country income levels (REPORT-HF): a prospective, multicentre, global cohort study

19. Author Correction: Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial

20. Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial

21. Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER

22. Abstract 18437: Efficacy and Safety of Dapagliflozin in Patients With Heart Failure and Previous Myocardial Infarction

23. Abstract 18170: Microvascular Complications of Type 2 Diabetes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction in the DELIVER Trial

29. Abstract 14120: Characteristics, Outcomes and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in People With HF and a History of CABG Surgery: A Pooled Analysis From DAPA-HF and DELIVER

32. Abstract 13678: Initial Decline in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: Insights From DELIVER

35. Abstract 13026: Effects of Dapagliflozin in Heart Failure, Type 2 Diabetes, and Neuropathy - A Patient-Level Meta-Analysis of DAPA-HF and DELIVER

37. Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial

42. Proteomics Identify Clinical Phenotypes and Predict Functional Outcomes in Heart Failure With Preserved Ejection Fraction: Insights From VITALITY-HFpEF.

44. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial

46. Prognostic Models for Mortality and Morbidity in Heart Failure With Preserved Ejection Fraction

Catalog

Books, media, physical & digital resources